ScripCargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need
ScripWhen Zevra Therapeutics, then known as KemPharm, bought arimoclomol for peanuts with its acquisition of Orphazyme in 2022, it looked like a great bit of business and further confirmation has come wi
ScripIpsen is making good progress in reducing its reliance on the acromegaly and neuroendocrine tumour blockbuster Somatuline, according to CEO David Loew who has heralded the launches of two rare disease
Pink SheetThe US Food and Drug Administration’s expectations for the timing of accelerated approval confirmatory trials came into clearer focus in 2024 with new policy documents and real-world examples. The age